Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:01:25.363Z.
Calculation as of: 2026-10-06T15:01:25.363Z.
Quote observation: 2026-10-06T15:00:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92e82853ec35d591c91e1857ba5f245e9338475f566e1ab86be3b7c1b83139db
EARNINGS YIELD
N/A
Artiva Biotherapeutics, Inc.
Market Cap
$346.77M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$352.79M
Earnings Yield
N/A
TTM Avg
2.17%
3Y Avg
3.20%
5Y Avg
4.68%
Market Cap
$356.03M
Earnings Yield
N/A
TTM Avg
0.64%
3Y Avg
0.64%
5Y Avg
0.64%
Market Cap
$356.59M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $346.77M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.79M | N/A | 2.17% | 3.20% | 4.68% |
| Opus Genetics, Inc. (IRD)vs › | $354.20M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $354.48M | 24.77% | 29.71% | 15.15% | 15.10% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.03M | N/A | 0.64% | 0.64% | 0.64% |
| Ocugen, Inc. (OCGN)vs › | $362.85M | N/A | 6.28% | 6.28% | 6.28% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $356.59M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $336.05M | 32.78% | 39.56% | 39.56% | 24.80% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $333.12M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $325.29M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
